CytomX (CTMX) CMO Yu-Waye Chu receives 75,000 RSUs and 300,000 options

Rhea-AI Filing Summary

CytomX Therapeutics Chief Medical Officer Yu-Waye Chu reported new equity awards. On February 2, 2026, Chu received 75,000 shares of Common Stock in the form of restricted stock units at a price of $0 per share. These RSUs convert into one share of Common Stock per unit, with one-third vesting each year on March 15, starting on March 15, 2027, subject to continued service.

On the same date, Chu was granted a stock option for 300,000 shares of Common Stock at an exercise price of $6.09 per share. One forty-eighth of the option vests monthly starting from February 2, 2026, becoming fully vested on the fourth anniversary of that date, also subject to continued service. After these transactions, Chu beneficially owns 210,725 shares of Common Stock, including 206,000 RSUs.

Insider Trade Summary

2 transactions reported

Mixed 2 txns

Insider Chu Yu-Waye

Role Chief Medical Officer

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	300,000	$0.00	--
Grant/Award	Common Stock	75,000	$0.00	--

Holdings After Transaction: Stock Option (Right to Buy) — 300,000 shares (Direct); Common Stock — 210,725 shares (Direct)

Footnotes (1)

1. Constitute restricted stock units ("RSUs") for which the Reporting Person is entitled to receive one (1) share of Common Stock for each RSU upon vesting. 1/3rd of the RSUs vest annually on March 15 of each year, with the first 1/3rd vesting on March 15, 2027, subject to the Reporting Person continuing as a service provider through each such date. Includes 206,000 RSUs. 1/48th of the shares subject to the option vest on each monthly anniversary measured from February 2, 2026 (the "Vesting Commencement Date"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service to the Issuer through each such date.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Chu Yu-Waye

(Last) (First) (Middle)

C/O CYTOMX THERAPEUTICS, INC.

151 OYSTER POINT BLVD., STE. 400

(Street)

SOUTH SAN FRANCISCO CA 94080

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
CytomX Therapeutics, Inc. [ CTMX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Medical Officer

3. Date of Earliest Transaction (Month/Day/Year)
02/02/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	02/02/2026		A		75,000(1)	A	$0	210,725(2)	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$6.09	02/02/2026		A		300,000		(3)	02/01/2036	Common Stock	300,000	$0	300,000	D

Explanation of Responses:

1. Constitute restricted stock units ("RSUs") for which the Reporting Person is entitled to receive one (1) share of Common Stock for each RSU upon vesting. 1/3rd of the RSUs vest annually on March 15 of each year, with the first 1/3rd vesting on March 15, 2027, subject to the Reporting Person continuing as a service provider through each such date.

2. Includes 206,000 RSUs.

3. 1/48th of the shares subject to the option vest on each monthly anniversary measured from February 2, 2026 (the "Vesting Commencement Date"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service to the Issuer through each such date.

	/s/ Christopher Ogden, as Attorney-in-Fact for Yu-Waye Chu	02/04/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transactions did CytomX (CTMX) report for Yu-Waye Chu on February 2, 2026?

Yu-Waye Chu received new RSUs and stock options on February 2, 2026. The filing shows a grant of 75,000 restricted stock units at $0 per share and a stock option for 300,000 shares at a $6.09 exercise price, both subject to vesting and continued service.

How many CytomX (CTMX) RSUs were granted to Chief Medical Officer Yu-Waye Chu?

Chu was granted 75,000 restricted stock units (RSUs). Each RSU represents the right to receive one share of CytomX Common Stock upon vesting. One-third of these RSUs vest annually on March 15, beginning March 15, 2027, contingent on Chu’s continued service.

What are the terms of Yu-Waye Chu’s 300,000-share stock option at CytomX (CTMX)?

The stock option covers 300,000 shares at a $6.09 exercise price. One forty-eighth of the option vests on each monthly anniversary of February 2, 2026. The option becomes fully vested and exercisable on the fourth anniversary, assuming continuous service with CytomX.

How do the new RSUs for CytomX (CTMX) CMO vest over time?

The 75,000 RSUs vest in three equal annual installments. One-third vests on March 15 of each year, starting March 15, 2027. Vesting depends on Yu-Waye Chu continuing as a service provider to CytomX through each applicable vesting date.

What is Yu-Waye Chu’s reported beneficial ownership of CytomX (CTMX) Common Stock after these grants?

Chu beneficially owns 210,725 shares of Common Stock after the transactions. This total includes 206,000 RSUs referenced in the footnotes. These figures combine time-based equity awards and any previously held shares as reported in the filing.

When will Yu-Waye Chu’s CytomX (CTMX) stock option be fully vested?

The 300,000-share stock option will be fully vested on the fourth anniversary of February 2, 2026. Vesting occurs monthly, with one forty-eighth vesting each month, assuming Chu continues to provide service to CytomX throughout the vesting period.

Are Yu-Waye Chu’s newly granted CytomX (CTMX) equity awards immediately exercisable or deliverable?

No, both the RSUs and stock options are subject to vesting schedules. RSUs vest in three annual tranches beginning March 15, 2027, while the stock options vest monthly over four years from February 2, 2026, conditioned on continued service.